270 related articles for article (PubMed ID: 34208064)
21. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.
Librizzi L; Noè F; Vezzani A; de Curtis M; Ravizza T
Ann Neurol; 2012 Jul; 72(1):82-90. PubMed ID: 22829270
[TBL] [Abstract][Full Text] [Related]
22. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice.
Baamonde A; Curto-Reyes V; Juárez L; Meana A; Hidalgo A; Menéndez L
Life Sci; 2007 Aug; 81(8):673-82. PubMed ID: 17692876
[TBL] [Abstract][Full Text] [Related]
23. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.
Larsen CM; Faulenbach M; Vaag A; Ehses JA; Donath MY; Mandrup-Poulsen T
Diabetes Care; 2009 Sep; 32(9):1663-8. PubMed ID: 19542207
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis.
Nikfar S; Saiyarsarai P; Tigabu BM; Abdollahi M
Rheumatol Int; 2018 Aug; 38(8):1363-1383. PubMed ID: 29737371
[TBL] [Abstract][Full Text] [Related]
25. Clinical benefits of intra-articular anakinra for persistent knee effusion.
Brown C; Toth A; Magnussen R
J Knee Surg; 2011 Mar; 24(1):61-5. PubMed ID: 21618940
[TBL] [Abstract][Full Text] [Related]
26. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats.
Vallejo S; Palacios E; Romacho T; Villalobos L; Peiró C; Sánchez-Ferrer CF
Cardiovasc Diabetol; 2014 Dec; 13():158. PubMed ID: 25518980
[TBL] [Abstract][Full Text] [Related]
27. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
28. Child Neurology: Initial Presentation of
Varughese RT; Karkare S; Poduri A; Kothare SV
Neurology; 2022 Aug; 99(5):208-211. PubMed ID: 35914944
[No Abstract] [Full Text] [Related]
29. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.
Sönnichsen A; Saulite I; Mangana J; Kerl K; Mehra T; Desislava I; Chang YT; Petrausch U; Schmid-Grendelmeier P; Hoetzenecker W; Cozzio A; Guenova E
J Dermatolog Treat; 2016 Oct; 27(5):436-8. PubMed ID: 26864191
[TBL] [Abstract][Full Text] [Related]
30. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
Zong M; Dorph C; Dastmalchi M; Alexanderson H; Pieper J; Amoudruz P; Barbasso Helmers S; Nennesmo I; Malmström V; Lundberg IE
Ann Rheum Dis; 2014 May; 73(5):913-20. PubMed ID: 23625983
[TBL] [Abstract][Full Text] [Related]
31. Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen's encephalitis.
Mochol M; Taubøll E; Sveberg L; Tennøe B; Berg Olsen K; Heuser K; Svalheim S
Epilepsy Behav Rep; 2021; 16():100462. PubMed ID: 34189453
[TBL] [Abstract][Full Text] [Related]
32. Long-term neuropsychological outcomes in children with febrile infection-related epilepsy syndrome (FIRES) treated with anakinra.
Shrestha A; Wood EL; Berrios-Siervo G; Stredny CM; Boyer K; Vega C; Nangia S; Muscal E; Eschbach K
Front Neurol; 2023; 14():1100551. PubMed ID: 36970506
[TBL] [Abstract][Full Text] [Related]
33. Extinguishing Febrile Infection-Related Epilepsy Syndrome: Pipe Dream or Reality?
Payne ET; Koh S; Wirrell EC
Semin Neurol; 2020 Apr; 40(2):263-272. PubMed ID: 32185792
[TBL] [Abstract][Full Text] [Related]
34. [Clinical features of CINCA syndrome: effects and problems of IL-1Ra].
Sugiura H; Matsubayashi T
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Apr; 30(2):108-13. PubMed ID: 17473513
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment.
Fang Z; Jiang J; Zheng X
Life Sci; 2023 Dec; 335():122276. PubMed ID: 37977354
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Anakinra Therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence.
Pillai K; Pillai J; Ling J
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398338
[TBL] [Abstract][Full Text] [Related]
37. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases.
Pazyar N; Feily A; Yaghoobi R
Curr Clin Pharmacol; 2012 Nov; 7(4):271-5. PubMed ID: 22794157
[TBL] [Abstract][Full Text] [Related]
38. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra).
Fischer-Betz R; Specker C; Schneider M
Clin Exp Rheumatol; 2011; 29(6):1021-3. PubMed ID: 22153586
[TBL] [Abstract][Full Text] [Related]
39. Bridging the Gap: Tailoring an Approach to Treatment in Febrile Infection-Related Epilepsy Syndrome.
Goh Y; Tay SH; Yeo LLL; Rathakrishnan R
Neurology; 2023 Jun; 100(24):1151-1155. PubMed ID: 36797068
[TBL] [Abstract][Full Text] [Related]
40. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.
Harrison SR; McGonagle D; Nizam S; Jarrett S; van der Hilst J; McDermott MF; Savic S
JCI Insight; 2016 May; 1(6):e86336. PubMed ID: 27699261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
